+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
AAV Gene Therapy Drugs Market - Global Forecast 2026-2032- Product Image
AAV Gene Therapy Drugs Market - Global Forecast 2026-2032- Product Image
Sale

AAV Gene Therapy Drugs Market - Global Forecast 2026-2032

  • Report

  • 198 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6145971
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The AAV Gene Therapy Drugs Market is projected to reach USD 12.03 Billion in 2026. It is expected to continue growing at a CAGR of 22.90%, reaching USD 41.88 Billion by 2032.

AAV Gene Therapy Drugs: Executive Overview

Adeno-associated virus (AAV) gene therapy drugs are medicines that use engineered viral vectors to deliver genetic material to target cells. The field is advancing through improved vector design, manufacturing, clinical development, and regulatory science. Its principal opportunities lie in treating serious diseases with limited therapeutic options, while its principal constraints include immune responses, tissue targeting, durability, manufacturing complexity, and high evidentiary requirements.

How Vector Science and Delivery Are Reshaping the Field

The landscape is shifting from proof-of-concept therapies toward more precise control of biodistribution, transgene expression, and repeat dosing. Developers are investigating capsid engineering, tissue-specific promoters, dose optimization, alternative administration routes, and methods to reduce pre-existing immunity. Manufacturing is also evolving through scalable upstream and downstream processes, improved analytics, and greater attention to product comparability when processes change.

Artificial Intelligence Accelerates Discovery, Development, and Oversight

Artificial intelligence is being applied to identify capsid candidates, model protein structure, predict tissue tropism, analyze clinical and manufacturing data, and improve trial design. These tools can help prioritize experiments and detect quality trends earlier, but they do not remove the need for laboratory validation, transparent datasets, reproducible methods, and regulatory review. The most durable impact is likely to come from combining machine learning with curated biological data, robust process controls, and expert interpretation.

Regional Dynamics: Regulation, Manufacturing, and Clinical Capability

North America has strong capabilities in translational research, biotechnology manufacturing, and advanced clinical development. Europe emphasizes harmonized regulatory expectations, specialized academic centers, and cross-border evidence generation. Asia-Pacific combines expanding research infrastructure with substantial patient populations and growing manufacturing capacity. Latin America is developing clinical and regulatory capabilities while facing access and infrastructure constraints. The Middle East is investing selectively in advanced healthcare and biotechnology platforms, whereas Africa remains focused on building research, diagnostic, manufacturing, and referral capacity needed for complex genetic medicines.

Group Perspectives: Cooperation and Policy Alignment

ASEAN countries are relevant to regional trial networks, health-system readiness, and technology transfer, although regulatory and infrastructure maturity varies. BRICS members span major research, manufacturing, and patient ecosystems, with collaboration shaped by differing rules and industrial policies. The European Union benefits from coordinated scientific and regulatory frameworks, while the G7 provides influential standards, research capacity, and financing channels. GCC states are strengthening specialized healthcare and biotechnology capabilities. NATO members collectively include many advanced biomedical ecosystems, but defense alignment does not replace national regulation, reimbursement policy, or clinical governance.

Country Insights Across Research, Regulation, and Access

The United States and Canada combine advanced clinical research, specialized manufacturing, and established regulatory expertise. The United Kingdom, France, Germany, Italy, and Spain contribute through academic medicine, European regulatory coordination, and national health-system assessment. China is expanding domestic innovation, clinical infrastructure, and manufacturing capabilities, while Japan and South Korea bring strong translational science and advanced biomanufacturing. Australia supports gene-therapy research through specialized institutions and a structured regulatory environment. India is strengthening biotechnology, clinical research, and manufacturing capacity. Brazil and Mexico are important Latin American centers for specialist care and clinical development, while Russia retains scientific and healthcare capabilities subject to regulatory, funding, and international collaboration conditions.

Priorities for Leaders Building Durable AAV Gene Therapy Programs

Industry leaders should prioritize clinically meaningful endpoints, transparent natural-history evidence, and early engagement with regulators and payers. Manufacturing strategies should establish scalable processes, validated analytical methods, supply resilience, and clear comparability plans before pivotal development. Programs should also assess pre-existing immunity, liver and other organ risks, long-term follow-up, and the feasibility of patient identification and treatment delivery. Responsible use of artificial intelligence requires documented validation, human oversight, cybersecurity, and controls against biased or irreproducible outputs. Partnerships with specialist hospitals, public agencies, and patient organizations can improve referral, consent, monitoring, and equitable access.

Methodology: Evidence-Based Assessment of the AAV Drug Landscape

This executive summary uses a structured qualitative assessment of AAV gene therapy drugs across scientific, clinical, manufacturing, regulatory, health-system, and geographic dimensions. Insights are derived from publicly available regulatory materials, peer-reviewed research, clinical-trial documentation, technical literature, and established healthcare-policy sources. Regional, group, and country observations are presented as contextual comparisons rather than numerical rankings. The assessment excludes market estimates, market shares, forecasts, and unsupported claims, and emphasizes patterns that can be corroborated through documented evidence.

Conclusion: Advancing AAV Therapies Through Precision and Discipline

AAV gene therapy drugs are progressing through a period of technical refinement and institutional learning. Future success will depend less on vector novelty alone than on integrated execution across targeting, safety, durability, manufacturing, evidence generation, regulation, and patient access. Organizations that pair rigorous translational science with resilient production, responsible artificial intelligence, and coordinated health-system planning will be better positioned to convert promising genetic approaches into dependable clinical care.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. AAV Gene Therapy Drugs Market, by Indication
7.1. Introduction
7.2. Hematology
7.2.1. Beta Thalassemia
7.2.2. Hemophilia A
7.2.3. Hemophilia B
7.3. Metabolic
7.3.1. Fabry Disease
7.3.2. Gaucher Disease
7.4. Musculoskeletal
7.4.1. Becker Muscular Dystrophy
7.4.2. Duchenne Muscular Dystrophy
7.5. Neurology
7.5.1. Alzheimer’s Disease
7.5.2. Parkinson’s Disease
7.5.3. Spinal Muscular Atrophy
7.6. Ophthalmology
7.6.1. Age Related Macular Degeneration
7.6.2. Leber’s Congenital Amaurosis
7.6.3. Retinal Dystrophy
8. AAV Gene Therapy Drugs Market, by Vector Type
8.1. Introduction
8.2. AAV2
8.3. AAV5
8.4. AAV8
8.5. AAV9
9. AAV Gene Therapy Drugs Market, by End-User
9.1. Introduction
9.2. Contract Manufacturing Organizations
9.3. Hospitals
9.4. Research Institutes
9.5. Specialty Clinics
10. AAV Gene Therapy Drugs Market, by Administration Route
10.1. Introduction
10.2. Intramuscular
10.3. Intrathecal
10.4. Intravenous
10.5. Subretinal
11. AAV Gene Therapy Drugs Market, by Therapy Stage
11.1. Introduction
11.2. Approved
11.3. Phase I
11.4. Phase II
11.5. Phase III
11.6. Preclinical
12. AAV Gene Therapy Drugs Market, by Modality
12.1. Introduction
12.2. Combination Therapy
12.3. Monotherapy
13. AAV Gene Therapy Drugs Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. AAV Gene Therapy Drugs Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. AAV Gene Therapy Drugs Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. 4D Molecular Therapeutics
17.2. Abeona Therapeutics Inc.
17.3. Adaptimmune Therapeutics PLC
17.4. Adverum Biotechnologies Inc.
17.5. Amgen Inc.
17.6. Astellas Pharma Inc.
17.7. BioMarin Pharmaceutical Inc.
17.8. bluebird bio Inc.
17.9. Capsida Biotherapeutics
17.10. CRISPR Therapeutics AG
17.11. CSL Behring LLC
17.12. F. Hoffmann-La Roche Ltd.
17.13. Krystal Biotech Inc.
17.14. MeiraGTx
17.15. Novartis AG
17.16. Pfizer Inc.
17.17. REGENXBIO Inc.
17.18. Sarepta Therapeutics Inc.
17.19. Spark Therapeutics Inc.
17.20. Takeda Pharmaceutical Company Limited
17.21. uniQure N.V.
17.22. Vertex Pharmaceuticals Incorporated
17.23. Voyager Therapeutics Inc.
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global AAV Gene Therapy Drugs Market, Years Considered for the Study
FIGURE 2. Global AAV Gene Therapy Drugs Market, Research Design
FIGURE 3. Global AAV Gene Therapy Drugs Market, Research Framework
FIGURE 4. Global AAV Gene Therapy Drugs Market, Data Triangulation
FIGURE 5. Global AAV Gene Therapy Drugs Market Size, 2017-2032 (USD Million)
FIGURE 6. Global AAV Gene Therapy Drugs Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 7. Global AAV Gene Therapy Drugs Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global AAV Gene Therapy Drugs Market Size, by Vector Type, 2025 vs 2032 (%)
FIGURE 9. Global AAV Gene Therapy Drugs Market Size, by Vector Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global AAV Gene Therapy Drugs Market Size, by End-User, 2025 vs 2032 (%)
FIGURE 11. Global AAV Gene Therapy Drugs Market Size, by End-User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global AAV Gene Therapy Drugs Market Size, by Administration Route, 2025 vs 2032 (%)
FIGURE 13. Global AAV Gene Therapy Drugs Market Size, by Administration Route, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2025 vs 2032 (%)
FIGURE 15. Global AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global AAV Gene Therapy Drugs Market Size, by Modality, 2025 vs 2032 (%)
FIGURE 17. Global AAV Gene Therapy Drugs Market Size, by Modality, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global AAV Gene Therapy Drugs Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global AAV Gene Therapy Drugs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global AAV Gene Therapy Drugs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global AAV Gene Therapy Drugs Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global AAV Gene Therapy Drugs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global AAV Gene Therapy Drugs Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global AAV Gene Therapy Drugs Market Segmentation & Coverage
TABLE 2. Global AAV Gene Therapy Drugs Market Size, 2017-2032 (USD Million)
TABLE 3. Global AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 4. Global Hematology Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Hematology Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Hematology Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Beta Thalassemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Beta Thalassemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Beta Thalassemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Hemophilia A Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Hemophilia A Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Hemophilia A Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Hemophilia B Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Hemophilia B Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Hemophilia B Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Metabolic Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Metabolic Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Metabolic Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Fabry Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Fabry Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Fabry Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Gaucher Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Gaucher Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Gaucher Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Musculoskeletal Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Musculoskeletal Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Musculoskeletal Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Becker Muscular Dystrophy Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Becker Muscular Dystrophy Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Becker Muscular Dystrophy Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Duchenne Muscular Dystrophy Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Duchenne Muscular Dystrophy Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Duchenne Muscular Dystrophy Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Neurology Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Neurology Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Neurology Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Alzheimer’s Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Alzheimer’s Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Alzheimer’s Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Parkinson’s Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Parkinson’s Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Parkinson’s Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Spinal Muscular Atrophy Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Spinal Muscular Atrophy Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Spinal Muscular Atrophy Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Ophthalmology Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Ophthalmology Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Ophthalmology Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Age Related Macular Degeneration Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Age Related Macular Degeneration Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Age Related Macular Degeneration Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Leber’s Congenital Amaurosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Leber’s Congenital Amaurosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Leber’s Congenital Amaurosis Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Retinal Dystrophy Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Retinal Dystrophy Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Retinal Dystrophy Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 59. Global AAV2 Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global AAV2 Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global AAV2 Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global AAV5 Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global AAV5 Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global AAV5 Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global AAV8 Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global AAV8 Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global AAV8 Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global AAV9 Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global AAV9 Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global AAV9 Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 72. Global Contract Manufacturing Organizations Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Global Contract Manufacturing Organizations Market Size, by Group, 2017-2032 (USD Million)
TABLE 74. Global Contract Manufacturing Organizations Market Size, by Country, 2017-2032 (USD Million)
TABLE 75. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 77. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 78. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 83. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 84. Global AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 85. Global Intramuscular Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Global Intramuscular Market Size, by Group, 2017-2032 (USD Million)
TABLE 87. Global Intramuscular Market Size, by Country, 2017-2032 (USD Million)
TABLE 88. Global Intrathecal Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Global Intrathecal Market Size, by Group, 2017-2032 (USD Million)
TABLE 90. Global Intrathecal Market Size, by Country, 2017-2032 (USD Million)
TABLE 91. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 93. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 94. Global Subretinal Market Size, by Region, 2017-2032 (USD Million)
TABLE 95. Global Subretinal Market Size, by Group, 2017-2032 (USD Million)
TABLE 96. Global Subretinal Market Size, by Country, 2017-2032 (USD Million)
TABLE 97. Global AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
TABLE 98. Global Approved Market Size, by Region, 2017-2032 (USD Million)
TABLE 99. Global Approved Market Size, by Group, 2017-2032 (USD Million)
TABLE 100. Global Approved Market Size, by Country, 2017-2032 (USD Million)
TABLE 101. Global Phase I Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Global Phase I Market Size, by Group, 2017-2032 (USD Million)
TABLE 103. Global Phase I Market Size, by Country, 2017-2032 (USD Million)
TABLE 104. Global Phase II Market Size, by Region, 2017-2032 (USD Million)
TABLE 105. Global Phase II Market Size, by Group, 2017-2032 (USD Million)
TABLE 106. Global Phase II Market Size, by Country, 2017-2032 (USD Million)
TABLE 107. Global Phase III Market Size, by Region, 2017-2032 (USD Million)
TABLE 108. Global Phase III Market Size, by Group, 2017-2032 (USD Million)
TABLE 109. Global Phase III Market Size, by Country, 2017-2032 (USD Million)
TABLE 110. Global Preclinical Market Size, by Region, 2017-2032 (USD Million)
TABLE 111. Global Preclinical Market Size, by Group, 2017-2032 (USD Million)
TABLE 112. Global Preclinical Market Size, by Country, 2017-2032 (USD Million)
TABLE 113. Global AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
TABLE 114. Global Combination Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 115. Global Combination Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 116. Global Combination Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 117. Global Monotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 118. Global Monotherapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 119. Global Monotherapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 120. Global AAV Gene Therapy Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 121. Asia-Pacific AAV Gene Therapy Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 122. Asia-Pacific AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 123. Asia-Pacific AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 124. Asia-Pacific AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
TABLE 125. Asia-Pacific AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
TABLE 126. Asia-Pacific AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 127. Asia-Pacific AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 128. Asia-Pacific AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 129. Asia-Pacific AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 130. Asia-Pacific AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 131. Asia-Pacific AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
TABLE 132. Asia-Pacific AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
TABLE 133. North America AAV Gene Therapy Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 134. North America AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 135. North America AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 136. North America AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
TABLE 137. North America AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
TABLE 138. North America AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 139. North America AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 140. North America AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 141. North America AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 142. North America AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 143. North America AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
TABLE 144. North America AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
TABLE 145. Latin America AAV Gene Therapy Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 146. Latin America AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 147. Latin America AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 148. Latin America AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
TABLE 149. Latin America AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
TABLE 150. Latin America AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 151. Latin America AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 152. Latin America AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 153. Latin America AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 154. Latin America AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 155. Latin America AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
TABLE 156. Latin America AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
TABLE 157. Europe AAV Gene Therapy Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 158. Europe AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 159. Europe AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 160. Europe AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
TABLE 161. Europe AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
TABLE 162. Europe AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 163. Europe AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 164. Europe AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 165. Europe AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 166. Europe AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 167. Europe AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
TABLE 168. Europe AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
TABLE 169. Middle East AAV Gene Therapy Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 170. Middle East AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 171. Middle East AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 172. Middle East AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
TABLE 173. Middle East AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
TABLE 174. Middle East AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 175. Middle East AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 176. Middle East AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 177. Middle East AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 178. Middle East AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 179. Middle East AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
TABLE 180. Middle East AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
TABLE 181. Africa AAV Gene Therapy Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 182. Africa AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 183. Africa AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 184. Africa AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
TABLE 185. Africa AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
TABLE 186. Africa AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 187. Africa AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 188. Africa AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 189. Africa AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 190. Africa AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 191. Africa AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
TABLE 192. Africa AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
TABLE 193. Global AAV Gene Therapy Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 194. ASEAN AAV Gene Therapy Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 195. ASEAN AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 196. ASEAN AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 197. ASEAN AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
TABLE 198. ASEAN AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
TABLE 199. ASEAN AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 200. ASEAN AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 201. ASEAN AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 202. ASEAN AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 203. ASEAN AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 204. ASEAN AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
TABLE 205. ASEAN AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
TABLE 206. GCC AAV Gene Therapy Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 207. GCC AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 208. GCC AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 209. GCC AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
TABLE 210. GCC AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
TABLE 211. GCC AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 212. GCC AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 213. GCC AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 214. GCC AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 215. GCC AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 216. GCC AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
TABLE 217. GCC AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
TABLE 218. European Union AAV Gene Therapy Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 219. European Union AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 220. European Union AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 221. European Union AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
TABLE 222. European Union AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
TABLE 223. European Union AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 224. European Union AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 225. European Union AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 226. European Union AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 227. European Union AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 228. European Union AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
TABLE 229. European Union AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
TABLE 230. BRICS AAV Gene Therapy Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 231. BRICS AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 232. BRICS AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 233. BRICS AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
TABLE 234. BRICS AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
TABLE 235. BRICS AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 236. BRICS AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 237. BRICS AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 238. BRICS AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 239. BRICS AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 240. BRICS AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
TABLE 241. BRICS AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
TABLE 242. G7 AAV Gene Therapy Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 243. G7 AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 244. G7 AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 245. G7 AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
TABLE 246. G7 AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
TABLE 247. G7 AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 248. G7 AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 249. G7 AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 250. G7 AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 251. G7 AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 252. G7 AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
TABLE 253. G7 AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
TABLE 254. NATO AAV Gene Therapy Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 255. NATO AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 256. NATO AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 257. NATO AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
TABLE 258. NATO AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
TABLE 259. NATO AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 260. NATO AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 261. NATO AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 262. NATO AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 263. NATO AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 264. NATO AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
TABLE 265. NATO AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
TABLE 266. Global AAV Gene Therapy Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 267. United States AAV Gene Therapy Drugs Market Size, 2017-2032 (USD Million)
TABLE 268. United States AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 269. United States AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 270. United States AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
TABLE 271. United States AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
TABLE 272. United States AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 273. United States AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 274. United States AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 275. United States AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 276. United States AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 277. United States AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
TABLE 278. United States AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
TABLE 279. Canada AAV Gene Therapy Drugs Market Size, 2017-2032 (USD Million)
TABLE 280. Canada AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 281. Canada AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 282. Canada AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
TABLE 283. Canada AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
TABLE 284. Canada AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 285. Canada AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 286. Canada AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 287. Canada AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 288. Canada AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 289. Canada AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
TABLE 290. Canada AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
TABLE 291. Mexico AAV Gene Therapy Drugs Market Size, 2017-2032 (USD Million)
TABLE 292. Mexico AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 293. Mexico AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 294. Mexico AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
TABLE 295. Mexico AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
TABLE 296. Mexico AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 297. Mexico AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 298. Mexico AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 299. Mexico AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 300. Mexico AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 301. Mexico AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
TABLE 302. Mexico AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
TABLE 303. Brazil AAV Gene Therapy Drugs Market Size, 2017-2032 (USD Million)
TABLE 304. Brazil AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 305. Brazil AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 306. Brazil AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
TABLE 307. Brazil AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
TABLE 308. Brazil AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 309. Brazil AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 310. Brazil AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 311. Brazil AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 312. Brazil AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 313. Brazil AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
TABLE 314. Brazil AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
TABLE 315. United Kingdom AAV Gene Therapy Drugs Market Size, 2017-2032 (USD Million)
TABLE 316. United Kingdom AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 317. United Kingdom AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 318. United Kingdom AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
TABLE 319. United Kingdom AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
TABLE 320. United Kingdom AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 321. United Kingdom AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 322. United Kingdom AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 323. United Kingdom AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 324. United Kingdom AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 325. United Kingdom AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
TABLE 326. United Kingdom AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
TABLE 327. Germany AAV Gene Therapy Drugs Market Size, 2017-2032 (USD Million)
TABLE 328. Germany AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 329. Germany AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 330. Germany AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
TABLE 331. Germany AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
TABLE 332. Germany AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 333. Germany AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 334. Germany AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 335. Germany AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 336. Germany AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 337. Germany AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
TABLE 338. Germany AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
TABLE 339. France AAV Gene Therapy Drugs Market Size, 2017-2032 (USD Million)
TABLE 340. France AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 341. France AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 342. France AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
TABLE 343. France AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
TABLE 344. France AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 345. France AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 346. France AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 347. France AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 348. France AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 349. France AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
TABLE 350. France AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
TABLE 351. Russia AAV Gene Therapy Drugs Market Size, 2017-2032 (USD Million)
TABLE 352. Russia AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 353. Russia AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 354. Russia AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
TABLE 355. Russia AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
TABLE 356. Russia AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
TABLE 357. Russia AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
TABLE 358. Russia AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 359. Russia AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 360. Russia AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 361. Russia AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
TABLE 362. Russia AAV Gene Therap

Companies Mentioned

  • 4D Molecular Therapeutics
  • Abeona Therapeutics Inc.
  • Adaptimmune Therapeutics PLC
  • Adverum Biotechnologies Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • BioMarin Pharmaceutical Inc.
  • bluebird bio Inc.
  • Capsida Biotherapeutics
  • CRISPR Therapeutics AG
  • CSL Behring LLC
  • F. Hoffmann-La Roche Ltd.
  • Krystal Biotech Inc.
  • MeiraGTx
  • Novartis AG
  • Pfizer Inc.
  • REGENXBIO Inc.
  • Sarepta Therapeutics Inc.
  • Spark Therapeutics Inc.
  • Takeda Pharmaceutical Company Limited
  • uniQure N.V.
  • Vertex Pharmaceuticals Incorporated
  • Voyager Therapeutics Inc.

Related Topics

Related Reports

Ophthalmic AAV Gene Therapy Market - Global Forecast 2026-2032 - Product Image

Ophthalmic AAV Gene Therapy Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
AAV Gene Therapy Injection Market - Global Forecast 2026-2032 - Product Image

AAV Gene Therapy Injection Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Gene Therapies in Ophthalmology - Competitive Landscape, 2026 - Product Image

Gene Therapies in Ophthalmology - Competitive Landscape, 2026

  • Report
  • 280 Pages
  • Global
From
Gene Therapy - Competitive Landscape, 2026 - Product Image

Gene Therapy - Competitive Landscape, 2026

  • Report
  • 550 Pages
  • Global
From
AAV Gene Therapy Market Outlook 2026-2034: Market Share, and Growth Analysis - Product Image

AAV Gene Therapy Market Outlook 2026-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.